Evaluation of a Fixed, Weight-Based Dose of 3-Factor Prothrombin Complex Concentrate Without Adjunctive Plasma Following
- PDF / 424,507 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 45 Downloads / 152 Views
ORIGINAL ARTICLE
Evaluation of a Fixed, Weight-Based Dose of 3-Factor Prothrombin Complex Concentrate Without Adjunctive Plasma Following Warfarin-Associated Intracranial Hemorrhage Kerry M. Mohrien • G. Morgan Jones Andrew B. Boucher • Lucas Elijovich
•
Ó Springer Science+Business Media New York 2014
Abstract Introduction Data regarding use of prothrombin complex concentrate (PCC) for international normalization ratio (INR) reversal in warfarin-associated intracranial hemorrhage (wICH) is variable with regards to dosages, adjunctive agents, and product choice. In 2012, we implemented a fixed, weight-based [30 IU/kg] dosing protocol of 3-factor PCC (3PCC) utilizing a rapid infusion rate and no requirement for fresh frozen plasma (FFP) following factor product administration. We aimed to K. M. Mohrien Department of Pharmacy, Temple University Hospital, 3401 N Broad St, Philadelphia, PA 19140, USA e-mail: [email protected] G. Morgan Jones (&) Department of Pharmacy, Methodist University Hospital, University of Tennessee Health Sciences Center, 1265 Union Avenue, Memphis, TN, USA e-mail: [email protected] G. Morgan Jones Department of Clinical Pharmacy, Neurology, and Neurosurgery, University of Tennessee Health Sciences Center, 1265 Union Avenue, Memphis, TN, USA A. B. Boucher Department of Neurosurgery, Emory Healthcare, 1365-B Clifton Road, Suite 6200, Atlanta, GA 30322, USA e-mail: [email protected] L. Elijovich Department of Neurology and Neurosurgery, University of Tennessee Health Science Center, Memphis, TN, USA e-mail: [email protected] L. Elijovich Semmes-Murphey Neurologic and Spine Institute, 6325 Humphreys Blvd, TN, Memphis 38120, USA
evaluate the impact of this protocol on immediate and delayed INR reversal in patients admitted with wICH in the absence of FFP co-administration. Methods We conducted a retrospective review of patients receiving 3PCC following wICH between January 1, 2012 and December 10, 2013. The primary objective was to determine the percentage of patients achieving goal INR (B1.4) following 3PCC administration. Patients were excluded if their bleed was not intracranial in origin, received a dose outside of the specified protocol, or were given FFP as an adjunctive agent. Results We included 35 patients with a mean presenting INR of 3.2 ± 1.3. Thirty patients (85.7 %) achieved goal INR (B1.4) following one dose of 3PCC. The mean INR after infusion of 3PCC was 1.3 ± 0.2. The median duration between 3PCC infusion and subsequent INR was 48.0 min (30–70.1 min). Vitamin K was utilized in 33 (94.3 %) patients. No patient experienced a thromboembolic event within 7 days of 3PCC administration. Conclusions Fixed, weight-based dosing of 3PCC without adjunctive FFP resulted in high rates of complete INR reversal without significant adverse events. Keywords Intracranial hemorrhage Prothrombin complex concentrate Warfarin Fresh frozen plasma Anticoagulation
Introduction Anticoagulation with warfarin is associated with numerous complications, the most significant being in
Data Loading...
